MODELLING THE FINANCIAL IMPACT OF SUPERSATURATED OXYGEN THERAPY AFTER PRIMARY PCI: A HOSPITAL PERSPECTIVE
Author(s)
Alex Veloz, MS;
ZOLL Medical, Pittsburgh, PA, USA
ZOLL Medical, Pittsburgh, PA, USA
OBJECTIVES: Even after primary percutaneous coronary interventions (pPCI), patients presenting with left anterior descending-ST-segment elevation myocardial infarction (LAD-STEMI) are at considerable risk for a variety of adverse events including heart failure (HF) and death. Supersaturated oxygen (SSO2) therapy involves the intracoronary infusion of hyperoxemic blood immediately after pPCI and has been shown to reduce all-cause mortality and HF one year after pPCI. The objective of this work was to assess the economic impact of introducing SSO2 therapy through a budget-impact model (BIM).
METHODS: A BIM was developed to compare the current standard of care to the implementation of SSO2therapy from a hospital perspective. The modelled hospital treated 20 patients eligible for SSO2 therapy over one year. Additional costs incurred by SSO2 therapy considered device and material costs and an additional 60 minutes spent in the operating room to perform the procedure. Patients eligible for SSO2 therapy are generally more complex cases, thus, the reimbursement codes varied appropriately between standard of care and intervention arm. Model inputs were extracted from published literature where possible and costs were inflated to 2023 USD. Both probabilistic sensitivity analysis and one-way sensitivity analysis (OWSA) was conducted to assess uncertainty and model drivers respectively.
RESULTS: Over one year, all-cause mortality and HF for 20 eligible patients were reduced by 2.84 and 1.28 events respectively. The model estimated overall savings of $139,693 (95% CrI: $76,239-$199,114) with SSO2therapy over a one-year period. The OWSA revealed the ratio of private payors and the reimbursement payments for various DRG codes as key drivers of results.
CONCLUSIONS: Adoption of SSO₂ is projected to reduce costs and improve outcomes for eligible post-PCI patients from the hospital perspective. This analysis suggests that SSO₂ therapy may offer an affordable option for hospitals treating high-risk STEMI populations.
METHODS: A BIM was developed to compare the current standard of care to the implementation of SSO2therapy from a hospital perspective. The modelled hospital treated 20 patients eligible for SSO2 therapy over one year. Additional costs incurred by SSO2 therapy considered device and material costs and an additional 60 minutes spent in the operating room to perform the procedure. Patients eligible for SSO2 therapy are generally more complex cases, thus, the reimbursement codes varied appropriately between standard of care and intervention arm. Model inputs were extracted from published literature where possible and costs were inflated to 2023 USD. Both probabilistic sensitivity analysis and one-way sensitivity analysis (OWSA) was conducted to assess uncertainty and model drivers respectively.
RESULTS: Over one year, all-cause mortality and HF for 20 eligible patients were reduced by 2.84 and 1.28 events respectively. The model estimated overall savings of $139,693 (95% CrI: $76,239-$199,114) with SSO2therapy over a one-year period. The OWSA revealed the ratio of private payors and the reimbursement payments for various DRG codes as key drivers of results.
CONCLUSIONS: Adoption of SSO₂ is projected to reduce costs and improve outcomes for eligible post-PCI patients from the hospital perspective. This analysis suggests that SSO₂ therapy may offer an affordable option for hospitals treating high-risk STEMI populations.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
MT1
Topic
Medical Technologies
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Cardiovascular Disorders (including MI, Stroke, Circulatory)